Frontiers in immunology · 2026
The safety and efficacy of chimeric antigen receptor-T cell therapy in solid malignancies: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Kunpeng, Li Lian, Yu Zhangneng, Li Dong, Jiang Jinting, Guo Zhicheng, Wang Liang, Zhang Hua, Xu Liangliang, Zhang Ming
Аннотация
INTRODUCTION: Chimeric antigen receptor (CAR)-T cell therapy has achieved remarkable success in hematologic malignancies, prompting its exploration in solid tumors. This systematic review and meta-analysis aimed to evaluate the safety and feasibility of CAR-T therapy for solid tumor treatment.
METHODS: We systematically searched PubMed, Cochrane Library, Embase, and Web of Science from database inception to June 1, 2026, for clinical studies evaluating CAR-T therapy in solid tumors. Primary outcomes included the incidence of any-grade and grade ≥3 adverse events (AEs); secondary outcomes were the overall response rate (ORR) and disease control rate (DCR). This review adhered to PRISMA guidelines and was registered with PROSPERO (CRD42024549048).
RESULTS: 52 studies with 712 patients were enrolled in our study. Lymphopenia (70%, grade≥3: 48%) was the most common adverse event. The pooled ORR and DCR were 13% (95%CI: 11-16%) and 63% (95%CI: 59-67%), respectively. Subgroup analysis indicated that the incidence of hematologic toxicity was significantly higher in patients who had received lymphodepletion, and intravenous delivery was associated with a higher risk of several AEs. Patients who had undergone lymphodepletion (LD) achieved higher ORR (p = 0.0002) and DCR (p = 0.0083). In comparison to regional delivery, intravenous infusion was associated with higher ORR (p = 0.0345).
CONCLUSION: CAR-T therapy demonstrates an acceptable safety profile for solid tumors. While lymphodepletion and intravenous delivery correlate with higher ORR and DCR, they also increase adverse event risks. Balancing therapeutic benefits and safety concerns therefore remains a critical consideration for clinical practice.
METHODS: We systematically searched PubMed, Cochrane Library, Embase, and Web of Science from database inception to June 1, 2026, for clinical studies evaluating CAR-T therapy in solid tumors. Primary outcomes included the incidence of any-grade and grade ≥3 adverse events (AEs); secondary outcomes were the overall response rate (ORR) and disease control rate (DCR). This review adhered to PRISMA guidelines and was registered with PROSPERO (CRD42024549048).
RESULTS: 52 studies with 712 patients were enrolled in our study. Lymphopenia (70%, grade≥3: 48%) was the most common adverse event. The pooled ORR and DCR were 13% (95%CI: 11-16%) and 63% (95%CI: 59-67%), respectively. Subgroup analysis indicated that the incidence of hematologic toxicity was significantly higher in patients who had received lymphodepletion, and intravenous delivery was associated with a higher risk of several AEs. Patients who had undergone lymphodepletion (LD) achieved higher ORR (p = 0.0002) and DCR (p = 0.0083). In comparison to regional delivery, intravenous infusion was associated with higher ORR (p = 0.0345).
CONCLUSION: CAR-T therapy demonstrates an acceptable safety profile for solid tumors. While lymphodepletion and intravenous delivery correlate with higher ORR and DCR, they also increase adverse event risks. Balancing therapeutic benefits and safety concerns therefore remains a critical consideration for clinical practice.